Sebastian-TradingExpertsEU

BioNTech Stock Will Soar With Its First-Mover Vaccine Advantage

Long
NASDAQ:BNTX   BIONTECH SE
NASDAQ:BNTX a German company and its american partner NYSE:PFE
will likely have a first-mover advantage in the coronavirus vaccine race in the U.S. This will affect both stocks, once the final vaccine results are in.

Assuming the bottom is in and we are about to continue the Trend as previously, im expecting a big move after the approval, so dont forget to take risk of the table!

The reason for this is that the two companies are expecting to be the first to produce large-scale results from their Phase 2/3 clinical trials in October, according to Barron’s.
Depending on how effective their vaccine is, the U.S. Food and Drug Administration may even grant it emergency-use authorization

The advantage of their trial is that it is large, involving more than 30,000 participants.
The FDA wants to see at least 50% efficacy in trials before granting any Covid-19 authorization.

Why BioNTechs Vaccine Looks Like a Winner

With Pfizer in the back FDA and President Donald Trump are likely to move quickly.
According to them even the first small study with 24 Persons that took their messenger RNA vaccine produced antibodies.
With a lower doses usage of the vaccine and developed antibodies after 28 days — at levels about two times higher than in normal, recovering Covid-19 patients.

BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 to Hong Kong SAR and Macao SAR
Also a Deal to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidat

This combined with the huge buying volume and market shifts will grant momentum for bigger goals.

Just think about what ccould happen when they get kinda a monopol situation going for them.

Thank you for take the time and reading this and as always stay storng in those shaky times!

Sebastian

Comments

Thank you for sharing your knowledge and expertise!
Reply
Thank you so much. I looked at finviz data on next years eps and also calculated expected earnings for next year, assuming all vaccine revenue hits next year 50/50 with Pfizer and the increase is huge for next year. I have a feeling it will break the $180 mark easy. Happy trading to you as well! Good luck to both of us!
Reply
Hey @avxhi13 thank you for the comment. To which Analysis are you refering to?
Well my personal sell target would be with the upcoming push around 140-150. Thats where MRNA and NVAX run into without even getting close to an FDA Approval. So it will be exciting.

Also planning on re enter when it shows a strong support level at the psychological mark at 100$
Becuase they develop more than only the coronavirus vaccine.

I wish you great trading! :)
Reply
Nice report. I believe the same as you. I do have a question: what price target do you believe the stock may reach when next years EPS is about 2,121% based on some analysis?
Thank you
Reply
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out